https://ibdeg.digitellinc.com/p/cf/ddw-conference-analysis-program-2021-8
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-1-wrap-up-17
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-2-wrap-up-26
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-3-wrap-up-33
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-1-wrap-up-42
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-2-wrap-up-47
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-3-wrap-up-57
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-1-wrap-up-63
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-2-wrap-up-70
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-3-wrap-up-76
https://ibdeg.digitellinc.com/p/cf/uegw-conference-analysis-program-2021-80
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-1-wrap-up-85
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-2-wrap-up-89
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-3-wrap-up-94
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-1-wrap-up-97
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-2-wrap-up-98
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-3-wrap-up-102
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-1-wrap-up-104
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-2-wrap-up-108
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-3-wrap-up-110
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-final-session-115
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-final-session-119
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-final-session-124
https://ibdeg.digitellinc.com/p/cf/ecco-congress-2022-132
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-1-wrap-up-135
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-1-wrap-up-140
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-1-wrap-up-145
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-2-wrap-up-150
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-2-wrap-up-155
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-2-wrap-up-160
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-final-session-165
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-final-session-170
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-final-session-175
https://ibdeg.digitellinc.com/p/cf/ecco-congress-2023-179
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-1-180
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-1-181
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-1-182
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-2-183
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-2-184
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-2-185
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-final-session-186
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-final-session-187
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-final-session-188
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-day-3-189
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-day-3-190
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-day-3-191
https://ibdeg.digitellinc.com/p/s/controlled-and-uncontrolled-studies-of-existing-therapies-and-safety-plenary-session-192
https://ibdeg.digitellinc.com/p/s/diagnostics-natural-history-and-epidemiology-plenary-session-193
https://ibdeg.digitellinc.com/p/s/new-molecules-new-applications-of-older-molecules-and-new-treatment-strategies-plenary-session-194